Bernstein lowered the firm’s price target on DexCom (DXCM) to $77 from $83 and keeps an Outperform rating on the shares. The firm notes sales grew 12% organic to $1.19B with 11% U.S. growth and 17% outside-U.S. growth. Margins were much better than expected at 22% adjusted operating margin, Bernstein adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $75 from $90 at Mizuho
- DexCom price target lowered to $81 from $83 at Raymond James
- DexCom price target raised to $100 from $95 at Canaccord
- DexCom price target lowered to $67 from $72 at Barclays
- Buy Rating Reaffirmed on Dexcom as Margin Strength and Global Patient Growth Offset U.S. CGM Concerns; Price Target Reset to $75